ipilimumab,nivolumab,durvalumab,vinorelbine,paclitaxel,carboplatin,cisplatin,gemcitabine,docetaxel,pemetrexed
bms,astrazeneca
['durva', 'aegean']
no concerning safety signals noted in aegean. rare to see aes lead to cancellation of surgery (1-2%). g3+ immune mediated aes in 4% with durvalumab and 2.5% with placebo. many of the listed aes expected with standard chemotherapy and surgery. #aacr23 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast #ITYSL #HereWeGo